Kazia set to raise $4m to improve cancer trials
MELBOURNE: Kazia Therapeutics will raise $4 million to improve its GDC-0084 and Cantrixil cancer programs.
MELBOURNE: Kazia Therapeutics will raise $4 million to improve its GDC-0084 and Cantrixil cancer programs.
FEATURED
Hospitals morphing into wellness and health precincts
Developers release plans for latest bayside living proposal
Technology will help urban spaces adapt in an ever-changing world
New funding agency to ‘supercharge’ community housing providers
Drug company deal delivers hope for dementia patients
Proactive alliances among stakeholders can lead to assisted living departments
INNOVATION
